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Type 2 diabetes makes a compelling case study for pub-
lic health action (1). The disease respects no boundaries. It
is increasingly common — occurring in both developed and
developing countries (2), in men and women, at earlier
ages than in past decades, and in persons of every race and
ethnic group, with a high prevalence in Hispanic/Latino
Americans and in other minority groups, including non-
Hispanic blacks, American Indians, Alaska Natives, Asian
Americans, and Native Hawaiian and other Pacific
Islanders (3). As noted by Martorell (4) and Saldaña (5),
family history and genetic factors appear to further
increase the risk for type 2 diabetes in Hispanic/Latino
Americans. In the United States, the prevalence of dia-
betes was estimated to be 18.2 million people (6.3% of the
population) in 2002 (3), with dramatic increases predicted
in the future (6).
The determinants of type 2 diabetes are largely under-
stood. Two of the most important risk factors, obesity and
physical inactivity, are modifiable.  The natural history
involves progression from prediabetes, a condition in
which blood glucose metabolism is abnormal (although not
yet in the diabetes range), to the development of type 2
diabetes. The rate of progression from prediabetes to type
2 diabetes is between 3% and 10% per year (7). However,
progression from prediabetes to diabetes can be prevented
or delayed with sustained weight loss and increased phys-
ical activity (8,9). The magnitude of the change needed for
primary prevention of type 2 diabetes is relatively modest:
a 7% to 10% weight loss and sustained moderate physical
activity, at least 30 minutes per day (10). Today, the num-
ber of adults with prediabetes in the United States is esti-
mated to be at least 41 million (3).
Type 2 diabetes leads to devastating health and eco-
nomic consequences for individuals, their families, and
society. The most serious complications include blindness,
kidney disease, lower-limb amputations, and acceleration
of coronary heart disease and stroke (3). After type 2 dia-
betes is diagnosed, treatment requires an increasingly
intensive and complex regimen to control glucose, blood
pressure, and lipids, in addition to ongoing preventive care
for the eyes, kidneys, and feet (11). Health care and com-
plications attributed to diabetes are costly: in 2002, the
total cost of diabetes was estimated to be $132 billion, $92
billion of which was spent on direct medical costs and $40
billion of which was spent on indirect costs, including dis-
ability, work loss, and premature mortality (12). Clearly,
ongoing access to high-quality health care is a paramount
concern for preventing complications and death from dia-
betes. Such care is expensive, and much of the cost of
drugs and supplies is not reimbursed, even for those with
insurance coverage (13). While it is improving, the quality
of clinical care for people with diabetes still falls short of
established guidelines (14). Because of continued increas-
es in the prevalence of obesity, the outlook for the future is
ominous — the health system will likely be overwhelmed
by type 2 diabetes (15).
The population groups at increased risk for diabetes,
including Hispanic/Latino Americans, suffer a dispropor-
tionate burden of disease, further exacerbated by poverty
and lack of access to health care (3,16). What public health
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services,
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions. Use of trade names is for identification only
and does not imply endorsement by any of the groups named above.
www.cdc.gov/pcd/issues/2005/jan/04_0119.htm • Centers for Disease Control and Prevention 1
Barbara A. Bowman, PhD, Frank Vinicor, MD, MPHVOLUME 2: NO. 1
JANUARY 2005
responses are likely to be effective in reducing the present
and future consequences of type 2 diabetes in population
groups, such as people living along the U.S.-Mexico bor-
der? And, how long will it take to begin to turn the tide?
As detailed by Cohen et al in the series of articles from
the Border Health Strategic Initiative, the solution to type
2 diabetes control must begin in the community (17).
Extensive dialogue is a first step in engaging communities
and identifying the priorities for community action. The
papers by Cohen and associates demonstrate how commu-
nities and researchers can — and must — collaborate to
assess targets for intervention and develop sustainable
solutions to control type 2 diabetes. Insights gained from
these interventions also can guide the development of
effective community-based approaches for primary pre-
vention of type 2 diabetes. Community-based participato-
ry research and mobilization are critical to create the evi-
dence base for elimination of health disparities, as shown
in a recent compendium of papers describing the experi-
ence of Racial and Ethnic Approaches to Community
Health (REACH) 2010 communities (18).
But having evidence is not enough. Improving the pub-
lic’s health will require rapid translation and dissemina-
tion of effective, community-based strategies for diabetes
prevention and control and the commitment to sustain and
reinforce these interventions (19). As shown by this prom-
ising initiative (17), collaboration across and within
national and state borders and communities will be essen-
tial and must involve the entire community: where people
live, work, play, and go to school. Improved clinical care
alone will not be sufficient. One strategy now being imple-
mented uses the essential public health services as strate-
gic levers to strengthen the public health response to dia-
betes (20). Development, implementation, and evaluation
of such strategies are needed urgently. We anticipate that
publication of the papers by Cohen et al, which describe
many challenges and some successes, will inspire readers
of Preventing Chronic Disease to share their own lessons
learned and promising approaches for public health action
to prevent and control type 2 diabetes.
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